Sinco Pharmaceuticals Holdings Limited (HKG:6833)

Market Cap	345.59M +1.8%
Revenue (ttm)	2.32B -26.1%
Net Income	38.78M -17.1%
EPS	0.02 -15.0%
Shares Out	2.03B
PE Ratio	8.99
Forward PE	n/a
Dividend	0.00 (1.01%)
Ex-Dividend Date	May 19, 2026

Volume	4,000
Open	0.1700
Previous Close	0.1660
Day's Range	0.1700 - 0.1700
52-Week Range	0.1520 - 0.2800
Beta	0.96
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 26, 2026

About HKG:6833

Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China. The company offers human albumin serum under the Octapharma, Octapamma, and Octenor name for the treatment of premature infants, hypovolemia, hypoproteinemia, neonatal hyperbilirubinemia, acute respiratory distress syndrome, cardiopulmonary bypass, special types of hemodialysis, and plasma exchange. It also provides Axetine, which is used for the ...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2011
• Employees: 261
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6833

Financial Performance

In 2025, HKG:6833's revenue was 2.08 billion, a decrease of -26.11% compared to the previous year's 2.82 billion. Earnings were 34.85 million, a decrease of -17.11%.

Financial numbers in CNY